Pfizer Inc. $PFE Shares Purchased by New England Professional Planning Group Inc.

New England Professional Planning Group Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 205.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,572 shares of the biopharmaceutical company’s stock after buying an additional 39,405 shares during the quarter. Pfizer accounts for about 0.6% of New England Professional Planning Group Inc.’s holdings, making the stock its 7th biggest position. New England Professional Planning Group Inc.’s holdings in Pfizer were worth $1,670,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC lifted its position in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new position in Pfizer during the 2nd quarter valued at about $26,000. Field & Main Bank bought a new stake in Pfizer during the 2nd quarter worth approximately $27,000. Bullseye Investment Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $28,000. Finally, Timbuktu Capital Management LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $29,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Scotiabank raised their target price on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Cantor Fitzgerald upped their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. HSBC increased their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Finally, Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.65.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts are watching Pfizer’s obesity pipeline for evidence of a potential long-term growth opportunity. A successful update could help offset concerns about slower growth elsewhere in the business. Pfizer Q3 preview: Analysts look to obesity pipeline amid diverging growth expectations
• Positive Sentiment: Pfizer’s roughly 6% dividend yield continues to appeal to income-oriented investors. At that yield, generating $500 in monthly dividend income would require approximately $106,454 invested, assuming the payout remains unchanged. How To Earn $500 a Month From Pfizer Stock Ahead of Q3 Earnings
• Neutral Sentiment: Pfizer is scheduled to report third-quarter results before the market open on November 3. The consensus forecast calls for earnings per share of $0.73 and revenue of $15.88 billion, making guidance and any changes to full-year expectations especially important. Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings
• Neutral Sentiment: Wall Street views are mixed, while Goldman Sachs expects an essentially in-line quarter. The divided outlook increases the likelihood of a significant stock reaction if Pfizer’s results or pipeline commentary differ from expectations. Pfizer Q3 preview: Goldman sees in-line quarter, pipeline in focus
• Negative Sentiment: The expected $0.73 quarterly EPS would be below the year-earlier result, signaling continued earnings pressure even though projected revenue of $15.88 billion would represent a solid quarterly base. What to expect from Pfizer’s Q3 earnings

Pfizer Price Performance

Shares of NYSE PFE opened at $30.73 on Tuesday. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $31.04. The stock has a fifty day simple moving average of $28.60 and a two-hundred day simple moving average of $26.82. The firm has a market cap of $175.16 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 2.00 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.6%. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.